Eli Lilly's Continued Growth Driven by GLP-1 Expansion and Strategic Acquisitions
Eli Lilly remains a strong buy due to its expanding GLP-1 franchise, particularly with Mounjaro and Zepbound driving significant revenue growth. The company also announced strategic acquisitions in May 2026 aimed at enhancing its pipeline.
Tickers: $LLY
Topics: acquisition Foundayo GLP-1 drugs Mounjaro Zepbound